S. Johnston

发表

Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study.

P. Fasching, H. Rugo, K. Tamura, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)

J. Huober, O. Trédan, S. Paluch-Shimon, 2022, Annals of Oncology.

Radiation‐induced morphoea treated with UVA‐1 phototherapy

L. Fearfield, L. Novaković, S. Johnston, 2014, Clinical and experimental dermatology.

MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer

P. Neven, G. Sledge, X. Pivot, 2019, Annals of Oncology.

Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer

I. Ellis, M. Dowsett, A. Tutt, 2014, Breast Cancer Research and Treatment.

MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)

S. Goel, A. Wardley, S. Im, 2019, Annals of Oncology.

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience

S. Chan, S. Johnston, A. Wardley, 2010, British Journal of Cancer.

Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors.

C. Osborne, M. Dowsett, C. Benz, 1997, Cancer research.

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

P. Neven, K. Gelmon, H. Rugo, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.

S Michiels, M Buyse, S Marguet, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance.

S. Johnston, S. Johnston, 2005, Endocrine-related cancer.

Complete excision with narrow margins provides equivalent local control to wider excision in breast conservation for invasive cancer

I. Smith, G. Gui, P. Osin, 2018, BJS open.

A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer.

P. Ellis, S. Johnston, I. Smith, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Point-of-care testing for bacterial infection in diabetic foot ulcers: a prospective cohort study.

L. Jonker, J. Schutter, S. Johnston, 2020, Journal of wound care.

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy

M. Dowsett, S. Pancholi, D. Evans, 2010, British Journal of Cancer.